39 results about "D-cycloserine" patented technology

The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure provides compositions and methods based on the use of D-cycloserine in combination with the neurogenic agent, which synergistically stimulates or activates the formation of new nerve cells.

There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.

The present invention provides a method of treating a neurodegenerative disorder in a patient, comprising administration to the patient a therapeutically effective amount of D-cycloserine and its derivatives.

Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and / or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors.

The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, closed head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of D-alanine (or a modified form thereof), provided that the composition is substantially free of D-cycloserine, and / or (ii) D-serine (or a modified form thereof), and / or (iii) 105 to 500 mg of D-cycloserine (or a modified form thereof), and / or (iv) N-methylglycine (or a modified form thereof).

The invention discloses an enrichment culture medium and belongs to the field of detection. The enrichment culture medium is characterized in that a formula contains beef liver powder, malt extract powder, yeast extract powder, sodium chloride, agar, ferric ammonium citrate, calcium lactate, D-seromycin, 2-ethoxymethylene-3,5-dihydroxy-y-pyrone, vitamin K1, sterile defiberized sheep blood and distilled water. Compared with the prior art, the enrichment culture medium plays roles in transporting and enriching.

Remedies for spinocerebellar degeneration or compositions for treating the same which contain as the active ingredient one or more members selected from among D-cycloserine, D-serine esters, D-serine and salts thereof. A method for treating spincerebellar degeneration which comprises administering to a patient with this disease in an efficacious dose of one or more members selected from among D-cycloserine, D-serine esters, D-serine and salts thereof.

The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, closed head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of D-alanine (or a modified form thereof), provided that the composition is substantially free of D-cycloserine, and / or (ii) D-serine (or a modified form thereof), and / or (iii) 105 to 500 mg of D-cycloserine (or a modified form thereof), and / or (iv) N-methylglycine (or a modified form thereof).

The invention provides methods and compositions for treating anxiety-related disorders in a subject. The methods include sublingually administering D-cycloserine to a subject with the anxiety-related disorder, either alone or in combination with extinction training.

Van A and Van B vancomycin resistant enterococci detection media as well as a method of selectively detecting Van A and Van B vancomycin resistant enterococci clinically important in vancomycin resistant enterococci from testing microorganisms or specimens using the media. The media for selectively detecting Van A and Van B VRE from testing microorganisms and specimens are media where enterococci can grow where vancomycin, D-cycloserine and D-lactate are added. Preferably 32-256 mug / ml of vancomycin, 1-64 mug / ml of D-cycloserine, and 0.025-0.8 mol / l of sodium lactate are added to culture medium where enterococci can grow.

A treatment for cancer is provided. The treatment may include administering a therapeutic amount of L-histidine, D-cycloserine, quisqualic acid or suramin or analogs thereof.

Methods are disclosed for improving treatment of various medical conditions via administration of D-cycloserine to facilitate extinction learning. Specifically, by administering D-cycloserine on a post-extinction training pre-sleep basis, subsequent to extinction training during the day, the methods can improve upon the known ability of D-cycloserine to facilitate extinction learning.

The present invention relates to mutants of lactic acid bacteria which are resistant towards the antibiotic D-cycloserine and / or functionally equivalent antibiotics and which were found to give an increased texture when grown in milk while maintaining the other growth properties of the parent strain. The present invention, furthermore, relates to compositions comprising such mutants, and to dairy products fermented with the lactic acid bacteria resistant towards D-cycloserine and / or functionally equivalent antibiotics.

The invention discloses a method for preparing D-cycloserine through a one-pot method. The method comprises: carrying out a reaction on 3-chloro-D-serine and thionyl chloride in a solvent to obtain anintermediate 3-chloro-D-alanyl chloride hydrochloride solution; preparing a 35% sodium hydroxide aqueous solution, cooling to a temperature of less than 0 DEG C, controlling the temperature at -5 to5 DEG C, and adding the 3-chloro-D-alanyl chloride hydrochloride solution; uniformly stirring after completing the adding, controlling the temperature at -5 to 5 DEG C, and adding a hydroxylamine hydrochloride solution; slowly heating to a temperature of 20-30 DEG C after the adding, and adjusting the pH value of the solution to 10.5-12.0 by adding a 35% sodium hydroxide aqueous solution; carryingout standing liquid separation after completing the reaction; taking the water phase, and concentrating to achieve a near dry state; adding methanol, dissolving, and filtering to obtain a methanol solution; cooling to a temperature of -5 to 5 DEG C, and adjusting the pH value of the solution to 6.0-6.5 with a 60% acetic acid methanol solution; and carrying out stirring crystallization, carrying out centrifugation, drying the obtained wet product to obtain crude D-cycloserine, and refining to obtain the D-cycloserine finished product. According to the present invention, the product prepared bythe method has a liquid phase purity of more than 99.6% and a specific rotation of more than +110 DEG.

Disclosed are a composition for alleviating ultraviolet irradiation-induced damage, which is stable and safe and can be used on a daily basis, and a pharmaceutical composition, an external skin preparation, a food composition and a medicine for cataract, each comprising aforesaid composition for alleviating ultraviolet irradiation-induced damage. Specifically disclosed is a composition for alleviating ultraviolet irradiation-induced damage which contains one or more kinds of compounds selected from the group consisting of methionine, D-serine and derivatives and / or salts of the same. The aforesaid composition may be an external preparation for the skin, an anti-wrinkle agent, a sunscreen agent, a medicinal composition for treating and / or preventing skin diseases, a food composition or a pharmaceutical product for cataract. In the aforesaid composition for alleviating ultraviolet irradiation-induced damage, the aforesaid methionine may be D-methionine, and the aforesaid D-serine derivative may be D-cycloserine.

The invention describes methods and compositions for alleviating medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical compound that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction, wherein D-cycloserine is the pharmaceutical compound that enhances learning. Representative afflictions include pain, mood disorders, anxiety disorders including performance anxiety, insomnia, female sexual dysfunction, chronic fatigue, autism spectrum disorders, fibromyalgia, and attention deficit-hyperactivity disorder.

The invention relates to a preparation method of D-cycloserine. The preparation method comprises steps of preparation of N-trifluoroacetyl-D-serine, preparation of (1-trifluoroacetylamino-2-hydroxyl) ethyl hydroxamate, preparation of D-4-trifluoroacetylamino-3-oxazolidinone and hydrolysis of D-4-trifluoroacetylamino-3-oxazolidinone. The preparation method has the benefits as follows: raw materials are easy to obtain, the reaction condition is mild, and the technological operation is simple; the racemization degree of D-cycloserine prepared with a synthetic route is reduced, the optical purity is improved, the product quality is stable, the follow-up three steps are performed with a 'one-pot' method, accordingly, emission of the three wastes and product loss are reduced, and the total yield of a reaction is improved.

The invention relates to a method used for increasing 2,3-butylene glycol yield. The method is mainly used for solving a problem of existing technology that yield of 2,3-butylene glycol is relatively low. According to the method, bacteria are subjected to high sugar resistance domestication firstly; the domesticated bacteria are used for fermentation culturing, and an antibiotic is added in fermentation culturing processes, wherein the antibiotic is at least one selected from penicillin, cephalosporin, bacillus, D-cycloserine, and the like which are capable of inhibiting cell wall synthesis, and polymyxin B, nystatin, amphotericin, or valinomycin which are capable of influencing cytomembrane functions, and adding concentration of the antibiotic ranges from 0.0001 to 5g / L. The method is capable of increasing 2,3-butylene glycol yield, and can be used for production of 2,3-butylene glycol.

The invention relates to a culture medium for isolating and counting Clostridium butyricum, belonging to the field of microorganism separation and counting. Including tryptone 15.0g, beef extract powder 3.0g, yeast extract powder 1.0g, sodium chloride 5.0g, L-cysteine ​​hydrochloride 0.5g, sodium thioglycolate 0.5g, xylose 10.0g, Bromothymol blue 0.04g, agar powder 15.0g, purified water 900ml, D-cycloserine 0.25g, kanamycin sulfate 0.012g, egg yolk 25ml. Compared with the prior art, the beneficial effects of the present invention are: first, the culture medium of the present invention can make Clostridium butyricum It can be clearly distinguished from other bacteria by visual observation, thereby achieving the purpose of isolating and counting Clostridium butyricum. Second, the effect is remarkable, direct and effective, and low in cost.

A culture medium enhancer suitable for isolating culture of brucella is prepared from erythritol, glucose, animal serum, vitamins, amino acid, cell growth factors and the like. The content of ingredients in one liter of distilled water is present in the description, wherein the ingredients includes glucose, erythritol, tryptose, sodium chloride, horse serum, niacin, vitamins, vitamin B1, D-cycloserine, methylhexyl ether, polymyxin B, bacitracin, cycloheximide, nystatin, zinc sulfate, manganese sulfate, copper chloride, cobaltous sulfate, boric acid, ferric trichloride and aluminum trichloride. By using the culture medium enhancer suitable for isolating culture of brucella, growth of brucella in the culture medium can be effectively promoted while the growth of interference bacteria is suppressed. The culture medium enhancer is high in university oriented to the isolating culture of brucella, low in cost and convenient to prepare and use.

The invention discloses a transport and enrichment culture medium and belongs to the field of detection. The transport and enrichment culture medium is characterized in that a formula contains beef liver powder, malt extract powder, yeast extract powder, sodium chloride, agar, ferric ammonium citrate, calcium lactate, D-seromycin, 2-ethoxymethylene-3,5-dihydroxy-y-pyrone, vitamin K1, casein phosphopeptides, sterile defiberized sheep blood and distilled water. Compared with the prior art, the transport and enrichment culture medium plays roles in transporting and enriching.

Methods are disclosed for treating dementia, including mild cognitive impairment, via administration of D-cycloserine, or a prodrug thereof, on a tolerance-inhibiting basis. Specifically, by administering D-cycloserine on a tolerance-inhibiting basis, tolerance to D-cycloserine is less likely than would occur via daily administration, enhancing benefits and reducing costs and side effects. Pharmaceutical compositions useful for the treatment of dementia are additionally disclosed.

The invention relates to an application of D-seromycin in preparing medicine for treating Morphine psychological dependence behavior caused by stress, which belongs to the medicine technical field. A glutamic acid system in brain plays an important role in drug addiction process, and N-methyl-D-aspartic acid (NMDA) receptor which can be combined with glutamic acid to play a physiological effect exists in central nervous system. The NMDA receptor can be functionally inhibited by acting on different recognition sites. At present more side effects are brought by completely inhibiting the NMDA receptor, so antagonist which not only can block the pathological activation of the NMDA receptor but also is free from influencing the physiological activity of the NMDA receptor is important to discover. DCS is a serine natural derivative and is combined with a glycine site in NMDA receptor NR1 subunit to play an effect of excitant, so that internal flow of calcium ions in cells can be increased, but no neurotoxicity is produced. Since the prepared medicine not only can partially excite the NMDA receptor, but also is free from influencing the physiological activity, the medicine has small side effect on the human body.

The invention relates to a synthetic method of a D-cycloserine intermediate. According to the method, 3-halo-D-alanine methyl ester or an acid salt of 3-halo-D-alanine methyl ester is prepared from D-serine methyl ester or an acid salt of D-serine methyl ester and a halogenating agent through reaction in an organic solvent, and is an important intermediate for preparing D-cycloserine. The synthetic method adopts a process simple and convenient to operate, is high in safety, mild in reaction condition, high in yield and low in cost, greatly reduces production of waste acid and is quite suitable for industrial production.